# An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

> **NCT02657343** · PHASE1,PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 25 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Ribociclib
- **DRUG:** T-DM1
- **DRUG:** Trastuzumab
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT02657343
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-09
- **Primary completion:** 2020-08-27
- **Final completion:** 2022-06-30
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2022-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02657343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02657343, "An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02657343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*